Clinical Trial Update: Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

An update on a Phase 2/Phase 3 trial comparing Pracytarabine to Regorafenib for hepatocellular carcinoma, focusing on efficacy and safety, with the study curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pracytarabine (Pracytarabine)
• Regorafenib (regorafenib)

Snippet

Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Conditions: HCC | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING